ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups Not Included Among Grants to Be Funded At Recommended Levels

November 11, 1983

More Concept Approvals By DCPC Board

May 18, 1984

Seven Organizations To Use NCI-Army Coding System.

September 1, 2000

Is a New Cancer Center Always a Good Thing? UCSD To Buy Las Vegas Center at Bankruptcy Sale

January 20, 2012

Trial: Decitabine Improves Survival in Myeloid Leukemia

July 29, 2011

Eight Firms Join AACR As Sustaining Members

April 25, 1997